Mawhiba Research Enrichment Program-2021, King Abdulaziz and His Companions Foundation for Giftedness and Creativity, Riyadh, Saudi Arabia.
Department of Clinical Pharmacy, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
J Biomol Struct Dyn. 2023 Nov;41(19):9865-9878. doi: 10.1080/07391102.2022.2148126. Epub 2022 Nov 20.
Acetylcholinesterase prevails in the healthy brain, with butyrylcholinesterase reflected to play a minor role in regulating brain acetylcholine (ACh) levels. However, BuChE activity gradually increases in patients with (AD), while AChE activity remains unaffected or decays. Both enzymes therefore represent legitimate therapeutic targets for ameliorating the cholinergic deficit considered to be responsible for the declines in cognitive, behavioural, and global functioning characteristic of AD. Current study described the synthesis of indole-based sulfonamide derivatives () and their biological activity. Synthesis of these scaffolds were achieved by mixing chloro-substituted indole bearing amine group with various substituted benzene sulfonyl chloride in pyridine, under refluxed condition to obtained desired products. All products were then evaluated for AchE and BuchE inhibitory potential compare with positive Donepezil as standard drug for both AchE and BchE having IC = 0.016 ± 0.12 and 0.30 ± 0.010 M respectively. In this regard analog was found potent having IC value 0.15 ± 0.050 M and 0.20 ± 0.10 for both and respectively. All other derivatives also found with better potential. All compounds were characterized by various techniques such as H, C-NMR and HREI-MS. In addition, biological activity was maintained to explore the bioactive nature of scaffolds and their protein-ligand interaction (PLI) was checked through molecular docking study.Communicated by Ramaswamy H. Sarma.
乙酰胆碱酯酶在健康的大脑中占主导地位,而丁酰胆碱酯酶被认为在调节大脑乙酰胆碱(ACh)水平方面作用较小。然而,在(AD)患者中,BuChE 活性逐渐增加,而 AChE 活性保持不变或下降。因此,这两种酶都是改善胆碱能缺陷的合理治疗靶点,胆碱能缺陷被认为是导致 AD 患者认知、行为和整体功能下降的原因。本研究描述了吲哚基磺酰胺衍生物()的合成及其生物学活性。这些支架的合成是通过将带有胺基的氯取代吲哚与各种取代的苯磺酰氯在吡啶中混合,在回流条件下进行的,以得到所需的产物。然后,所有产物都被评估了对乙酰胆碱酯酶和丁酰胆碱酯酶的抑制潜力,与阳性对照多奈哌齐(Donepezil)进行比较,作为乙酰胆碱酯酶和丁酰胆碱酯酶的标准药物,其 IC = 0.016 ± 0.12 和 0.30 ± 0.010 M 分别。在这方面,类似物被发现具有很强的潜力,其 IC 值分别为 0.15 ± 0.050 M 和 0.20 ± 0.10。所有其他衍生物也具有更好的潜力。所有化合物都通过各种技术进行了表征,如 H、C-NMR 和 HREI-MS。此外,还进行了生物活性测试,以探索支架的生物活性,并通过分子对接研究检查其蛋白质-配体相互作用(PLI)。由 Ramaswamy H. Sarma 传达。